A Phase 2 Study of Cabiralizumab (BMS-986227 FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without Chemotherapy in Patients with Advanced Pancreatic Cancer relating to BMS Compounds: BMS-986227 FPA008
Brief description of study
If you have been diagnosed with pancreatic cancer which has progressed during or after at least one line of systemic chemotherapy, you may qualify for this Phase 2 study. The main goal of this study is to test the anti-tumor efficacy of the combination of cabiralizumab (BMS-986227) and nivolumab with and without chemotherapy for the treatment of advance/metastatic pancreatic cancer.
Clinical Study Identifier: s18-00045
ClinicalTrials.gov Identifier: NCTs18-00045
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
